<DOC>
	<DOC>NCT01797276</DOC>
	<brief_summary>Open Label access to DCA as continued treatment for congenital lactic acidosis.</brief_summary>
	<brief_title>Dichloroacetate Treatment of Congenital Lactic Acidosis Phase B: Open Label</brief_title>
	<detailed_description>Subjects who participated in a Phase 3 Randomized Controlled Trial of DCA for treatment of Congenital Lactic Acidosis (CLA) are eligible to continue treatment with investigational medication DCA at the same dose of 25mg/kg/day. Study participants must travel to the study site for bi-annual evaluation by the study investigator. Bi-annual evaluation will include an interim medical history review, physical exam, blood collection for DCA trough level, and urine pregnancy testing (if indicated).</detailed_description>
	<mesh_term>Acidosis</mesh_term>
	<mesh_term>Acidosis, Lactic</mesh_term>
	<criteria>Diagnosis of congenital lactic acidosis Participation in Study: #1831992: Dichloroacetate Treatment of Congenital Lactic Acidosis Intolerance to DCA</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Dichloroacetate (DCA)</keyword>
	<keyword>Congenital Lactic Acidosis (CLA)</keyword>
	<keyword>acidosis</keyword>
	<keyword>orphan disease</keyword>
</DOC>